title: The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma.
abstract: Patients with Hodgkin lymphoma are usually cured by primary therapy using chemotherapy alone or combined modality therapy with external beam radiation. Patients who do not experience a complete remission or those who experience relapse may by salvaged by high-dose therapy and autologous hematopoietic stem cell transplantation (ASCT). Success of this approach is largely dependent on the tumor being sensitive to salvage chemotherapy before transplant. More studies are showing the predictive value of functional imaging in this setting. Allogeneic hematopoietic stem cell transplantation has greater risk of nonrelapse mortality and is generally reserved for patients who experience relapse post-ASCT, but may provide long-term survival for some patients through graft-versus-tumor immune effects.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, Washington 98104-1029, USA.
authors.forename: Leona
authors.initials: L
authors.lastname: Holmberg
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
mesh_terms: D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008212:Lymphocyte Depletion; D060046:Maintenance Chemotherapy; D016609:Neoplasms, Second Primary / Q000209:etiology; D049268:Positron-Emission Tomography; D011379:Prognosis; D012008:Recurrence; D016879:Salvage Therapy; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous